Clinical trials: Inflammatory Bowel Diseases (IBD)
Inflammation, Crohn's Disease
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.
- Trial name
- NCT01203631
- Testing
- NNC 0142-0000-0002
- Where
- 23 sites in United States, Belgium and 6 more
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis
Several oral mesalazine (5-ASA) formulations exist, but the regimes require several tablets per day. Such regimens are not ideal and can interfere with normal daily activities of patients.
- Trial name
- EASI (NCT04133194)
- Testing
- Mesalazine
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Flemming Bendtsen
Ulcerative Colitis
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
- Trial name
- NCT00036439
- Testing
- Infliximab
- Volunteers
- 364 people
- Sponsor
- Centocor, Inc.
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- NCT06023030
- Where
- 104 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
- Trial name
- ECO-RESET (NCT03759041)
- Testing
- Vancomycin Pre-Treatment, SER-287
- Where
- 93 sites in United States, Canada
- Volunteers
- 203 people
- Sponsor
- Seres Therapeutics, Inc.
Ulcerative Colitis
Mind/Body Medicine and IBD Flare-Up
Ulcerative Colitis is an Inflammatory Bowel disease that is a life-long, relapsing disabling disorder. Current treatments for Ulcerative Colitis are not satisfactory.
- Trial name
- NCT00568256
- Testing
- Mind/Body Courses
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Rush University Medical Center
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS)
Sirolimus for Autoimmune Disease of Blood Cells
Treatment for patients with autoimmune destruction of blood cells is poor. The part of the body that fights infections is called the immune system and white blood cells (WBCs) are part of the immune system.
- Conditions
- Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT00392951
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Ulcerative Colitis
Dynamic Changes of Gut Microbiota in UC After FMT
A prospective study to investigate the dynamic changes of gut microbiota through colonic transendoscopic enteral tubing in patients with ulcerative colitis after fecal microbiota transplantation.
- Trial name
- NCT03949257
- Testing
- colonic transendoscopic enteral tubing
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases
This study aims to identify perceived barriers and facilitators to regular physical activity among children and adolescents with inflammatory bowel disease (IBD) followed in pediatric gastroenterology.
- Trial name
- Feels-Mici (NCT07383844)
- Testing
- IMPACT-III questionnaires, Data collection: CAPAS-Q, semi-structured interview
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Fondation Lenval
Crohn Disease
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
- Trial name
- MIRIAD (NCT06997965)
- Testing
- Mirikizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Alimentiv Inc.
Mild-to-moderate Ulcerative Colitis
Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study)
The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC) disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms and faecal calprotectin (FC) (substance that is…
- Trial name
- OPTIMISE (NCT04340895)
- Testing
- Faecal Calprotectin Home Test, PRO-2 Scoring
- Where
- 42 sites in Czechia, Hungary and 4 more
- Volunteers
- 250 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease
Observational Investigation of the CDED in a Real World IBD Clinic
A prospective observational study, which will follow a cohort of adult CD patients who are prescribed the Crohn disease exclusion diet (CDED) during their routine clinical dietary therapy.
- Trial name
- NCT05554445
- Where
- 2 sites in Israel
- Volunteers
- 1,000 people
- Sponsor
- Eli Sprecher, MD
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab.
- Trial name
- SHINE-1 (NCT04004611)
- Testing
- Mirikizumab
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases, Crohn Disease
Study Evaluating the Persistence, Efficacy and Tolerability of Methotrexate in Inflammatory Bowel Disease Patients
Methotrexate is one of the immunosuppressants used in chronic inflammatory bowel disease (IBD). It is indicated as monotherapy for induction and maintenance treatment of Crohn's disease (CD), or in combination with anti-tumor…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- MICI-METHO (NCT05927064)
- Where
- France
- Volunteers
- 1,282 people
- Sponsor
- Central Hospital, Nancy, France
Crohn's Disease
Study of Antibiotics in the Treatment of Colonic Crohn's Disease
Crohn's disease (CD) is a form of inflammatory bowel disease that can affect any part of the digestive system. Symptoms of this chronic illness include abdominal pain, bloating, nausea, vomiting, and diarrhea.
- Trial name
- NCT00257699
- Testing
- ciprofloxacin, metronidazole
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Mount Sinai Hospital, Canada
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Crohn Disease
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment.
- Trial name
- NCT02209792
- Testing
- BIBR 796 BS, 5 mg, BIBR 796 BS, 20 mg
- Volunteers
- 284 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
The purpose of this study is to understand the immune response activated in the human gastrointestinal tract by Trichuris Suis Ova (TSO) in patients with ulcerative colitis.
- Trial name
- MUCUS (NCT01433471)
- Testing
- Trichuris suis ova
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.